Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner.

Yoo LI, Liu DW, Le Vu S, Bronson RT, Wu H, Yuan J.

Cancer Res. 2006 Feb 15;66(4):1929-39.

2.

Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.

Foth M, Ahmad I, van Rhijn BW, van der Kwast T, Bergman AM, King L, Ridgway R, Leung HY, Fraser S, Sansom OJ, Iwata T.

J Pathol. 2014 Jun;233(2):148-58. doi: 10.1002/path.4334. Epub 2014 Mar 31.

3.

Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.

Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y, Hamada K, Yajima N, Kawahara K, Sasaki M, Tsuchiya N, Enomoto K, Mak TW, Nakano T, Habuchi T, Suzuki A.

Cancer Res. 2006 Sep 1;66(17):8389-96.

4.

Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.

Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J.

Oncogene. 2009 Sep 17;28(37):3307-19. doi: 10.1038/onc.2009.181. Epub 2009 Jul 13.

5.

Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.

Bjerke GA, Yang CS, Frierson HF, Paschal BM, Wotton D.

Oncogene. 2014 Jul 10;33(28):3660-7. doi: 10.1038/onc.2013.342. Epub 2013 Sep 2.

6.

Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.

Wang Z, Xu D, Ding HF, Kim J, Zhang J, Hai T, Yan C.

Oncogene. 2015 Sep 17;34(38):4975-84. doi: 10.1038/onc.2014.426. Epub 2014 Dec 22.

7.

Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.

Zhong C, Saribekyan G, Liao CP, Cohen MB, Roy-Burman P.

Cancer Res. 2006 Feb 15;66(4):2188-94.

8.

MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.

Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, Wang VM, Senturk S, Fellmann C, Ding D, Beinortas T, Kleinman D, Chen M, Sordella R, Wilkinson JE, Castillo-Martin M, Cordon-Cardo C, Robinson BD, Trotman LC.

Cancer Discov. 2015 Jun;5(6):636-51. doi: 10.1158/2159-8290.CD-14-1113. Epub 2015 Mar 31.

9.

Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium.

Fu Y, Wey S, Wang M, Ye R, Liao CP, Roy-Burman P, Lee AS.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19444-9. doi: 10.1073/pnas.0807691105. Epub 2008 Nov 25.

10.

Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C, Sun TT, Wu XR.

J Clin Invest. 2007 Feb;117(2):314-25. Epub 2007 Jan 25.

11.

p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control.

Bai F, Pei XH, Pandolfi PP, Xiong Y.

Mol Cell Biol. 2006 Jun;26(12):4564-76.

12.

Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.

Abou-Kheir WG, Hynes PG, Martin PL, Pierce R, Kelly K.

Stem Cells. 2010 Dec;28(12):2129-40. doi: 10.1002/stem.538.

13.

Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.

Choi HJ, Chung TW, Kang SK, Lee YC, Ko JH, Kim JG, Kim CH.

Glycobiology. 2006 Jul;16(7):573-83. Epub 2006 Mar 30.

PMID:
16574813
14.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
15.

Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model.

Korsten H, Ziel-van der Made A, Ma X, van der Kwast T, Trapman J.

PLoS One. 2009 May 22;4(5):e5662. doi: 10.1371/journal.pone.0005662.

16.

Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha.

Nemenoff RA, Simpson PA, Furgeson SB, Kaplan-Albuquerque N, Crossno J, Garl PJ, Cooper J, Weiser-Evans MC.

Circ Res. 2008 May 9;102(9):1036-45. doi: 10.1161/CIRCRESAHA.107.169896. Epub 2008 Mar 13.

PMID:
18340011
17.

PTEN, more than the AKT pathway.

Blanco-Aparicio C, Renner O, Leal JF, Carnero A.

Carcinogenesis. 2007 Jul;28(7):1379-86. Epub 2007 Mar 6. Review.

PMID:
17341655
18.

Gata3 antagonizes cancer progression in Pten-deficient prostates.

Nguyen AH, Tremblay M, Haigh K, Koumakpayi IH, Paquet M, Pandolfi PP, Mes-Masson AM, Saad F, Haigh JJ, Bouchard M.

Hum Mol Genet. 2013 Jun 15;22(12):2400-10. doi: 10.1093/hmg/ddt088. Epub 2013 Feb 20.

PMID:
23428429
19.

PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.

Fang J, Ding M, Yang L, Liu LZ, Jiang BH.

Cell Signal. 2007 Dec;19(12):2487-97. Epub 2007 Aug 15.

20.

Supplemental Content

Support Center